Moreover, CD133+ Ovarian cancer cell lines have been very recently shown to exhibit enhanced resistance to platinum-based therapy, and to form more aggressive tumor xenografts at a lower inoculum than their CD133- progeny [27,28]. This evidence concerns the gene PROM1 and ovarian carcinoma.